Immunotherapy-chemotherapy treatment coupled with in-depth genomic analyses leads to improved survival for patients with mesothelioma

Combining the immunotherapy agent durvalumab with the chemotherapy agents pemetrexed and cisplatin or carboplatin may provide a new treatment option for patients who have inoperable pleural mesothelioma, a cancer of the tissues lining the lungs, according to a phase II clinical trial.

from Top Health News -- ScienceDaily https://ift.tt/3mVBwd3